Phase II Trial of Pralatrexate (10-Propargyl-10-deazaaminopterin, PDX) in Patients with Unresectable Malignant Pleural Mesothelioma
- 1 April 2007
- journal article
- research article
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 2 (4) , 317-320
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- An Overview of Chemotherapy for MesotheliomaHematology/Oncology Clinics of North America, 2005
- Modified RECIST criteria for assessment of response in malignant pleural mesotheliomaAnnals of Oncology, 2004
- Mesothelioma Trends in the United States: An Update Based on Surveillance, Epidemiology, and End Results Program Data for 1973 through 2003American Journal of Epidemiology, 2004
- Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural MesotheliomaJournal of Clinical Oncology, 2003
- Phase II Study of Pemetrexed With and Without Folic Acid and Vitamin B12 as Front-Line Therapy in Malignant Pleural MesotheliomaJournal of Clinical Oncology, 2003
- Constructing the Kähler and the symplectic structures from certain spinors on 4-manifoldsProceedings of the American Mathematical Society, 2000
- Edatrexate (10-ethyl-deaza-aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesotheliomaCancer, 1999
- A new analogue of 10-deazaaminopterin with markedly enhanced curative effects against human tumor xenografts in miceCancer Chemotherapy and Pharmacology, 1998
- High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II studyBritish Journal of Cancer, 1992
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989